Top-Rated Stocks NYSE:PEN Penumbra - PEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $263.81 -1.38 (-0.52%) (As of 02/3/2023 12:01 PM ET) Add Compare Share Share Today's Range$259.75▼$266.1550-Day Range$195.94▼$265.1952-Week Range$114.86▼$266.63Volume31,359 shsAverage Volume307,485 shsMarket Capitalization$10.02 billionP/E RatioN/ADividend YieldN/APrice Target$245.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Penumbra MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.0% Downside$245.25 Price TargetShort InterestBearish10.46% of Float Sold ShortDividend StrengthN/ASustainability-1.25Upright™ Environmental ScoreNews Sentiment0.25Based on 16 Articles This WeekInsider TradingSelling Shares$5.81 M Sold Last QuarterProj. Earnings Growth600.00%From $0.14 to $0.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector463rd out of 1,029 stocksSurgical & Medical Instruments Industry50th out of 107 stocks 2.5 Analyst's Opinion Consensus RatingPenumbra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $245.25, Penumbra has a forecasted downside of 7.0% from its current price of $263.81.Amount of Analyst CoveragePenumbra has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.46% of the float of Penumbra has been sold short.Short Interest Ratio / Days to CoverPenumbra has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Penumbra has recently decreased by 0.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPenumbra does not currently pay a dividend.Dividend GrowthPenumbra does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePenumbra has received a 47.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.Environmental SustainabilityThe Environmental Impact score for Penumbra is -1.25. Previous Next 2.4 News and Social Media Coverage News SentimentPenumbra has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Penumbra this week, compared to 3 articles on an average week.Search Interest15 people have searched for PEN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,808,660.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Penumbra is held by insiders.Percentage Held by Institutions82.42% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Penumbra are expected to grow by 600.00% in the coming year, from $0.14 to $0.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Penumbra is -321.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Penumbra is -321.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPenumbra has a P/B Ratio of 10.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Penumbra (NYSE:PEN) StockPenumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.Read More Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Email Address PEN Stock News HeadlinesFebruary 3, 2023 | americanbankingnews.comPenumbra (NYSE:PEN) PT Raised to $285.00February 3, 2023 | americanbankingnews.comTruist Financial Raises Penumbra (NYSE:PEN) Price Target to $284.00February 3, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.February 3, 2023 | americanbankingnews.comPenumbra (NYSE:PEN) Hits New 1-Year High Following Analyst UpgradeFebruary 1, 2023 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) Director Don W. Kassing Sells 693 SharesFebruary 1, 2023 | americanbankingnews.comPenumbra (NYSE:PEN) PT Raised to $270.00January 31, 2023 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) Receives $238.55 Consensus Price Target from AnalystsJanuary 30, 2023 | americanbankingnews.comPiper Sandler Initiates Coverage on Penumbra (NYSE:PEN)February 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 29, 2023 | finance.yahoo.comInvesting in Penumbra (NYSE:PEN) five years ago would have delivered you a 160% gainJanuary 28, 2023 | americanbankingnews.comInsider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells $5,005,000.00 in StockJanuary 26, 2023 | finance.yahoo.comPenumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023January 16, 2023 | marketwatch.comNeurology Devices Market With Highly Productive Segment To Expand Outstandingly | Including 94 Pages ReportJanuary 10, 2023 | finance.yahoo.comPENUMBRA LAUNCHES LATEST INNOVATION IN MECHANICAL THROMBECTOMY: LIGHTNING FLASH™December 19, 2022 | finance.yahoo.comPenumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNovember 28, 2022 | msn.comHoliday Arts Guide: From Santa to Scrooge, there are plenty of seasonal stage offeringsNovember 15, 2022 | finance.yahoo.comPenumbra Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding REAL® System PlatformNovember 9, 2022 | finance.yahoo.comPenumbra Third Quarter 2022 Earnings: EPS Beats ExpectationsNovember 4, 2022 | finance.yahoo.comPenumbra's Lightning Flash Launch Pushed Into Next Year, Trims FY22 ForecastsNovember 3, 2022 | finance.yahoo.comPenumbra (PEN) Tops Q3 Earnings and Revenue EstimatesOctober 19, 2022 | finance.yahoo.comGlobal Thrombectomy Devices Market Research Report 2021-2032 - Yahoo FinanceOctober 13, 2022 | washingtonpost.comMosaic Theater's 'Till Trilogy' arrives with uncanny timeliness - The Washington PostOctober 12, 2022 | benzinga.comWhat 8 Analyst Ratings Have To Say About Penumbra - Penumbra (NYSE:PEN) - BenzingaOctober 10, 2022 | finance.yahoo.comWhy Celsius Doxxed Hundreds of Thousands of Users - Yahoo FinanceOctober 6, 2022 | benzinga.comPenumbra, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 3, 2022 - P - BenzingaOctober 6, 2022 | finance.yahoo.comPenumbra, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 3, 2022October 6, 2022 | benzinga.comAnalyst Ratings for Penumbra - Penumbra (NYSE:PEN) - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Email Address PEN Company Calendar Last Earnings8/09/2021Today2/03/2023Next Earnings (Confirmed)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:PEN CUSIPN/A CIK1321732 Webwww.penumbrainc.com Phone(510) 748-3200Fax510-748-3232Employees3,800Year FoundedN/APrice Target and Rating Average Stock Price Forecast$245.25 High Stock Price Forecast$285.00 Low Stock Price Forecast$185.00 Forecasted Upside/Downside-7.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E Ratio1,884.36 P/E GrowthN/ANet Income$5.28 million Net Margins-3.68% Pretax Margin-5.32% Return on Equity0.45% Return on Assets0.33% Debt Debt-to-Equity Ratio0.03 Current Ratio5.23 Quick Ratio2.92 Sales & Book Value Annual Sales$747.59 million Price / Sales13.40 Cash Flow$1.17 per share Price / Cash Flow224.97 Book Value$25.53 per share Price / Book10.33Miscellaneous Outstanding Shares37,980,000Free Float35,890,000Market Cap$10.02 billion OptionableOptionable Beta0.50 Key ExecutivesAdam ElsesserChairman, President & Chief Executive OfficerBen SorciExecutive Vice President-OperationsMaggie S. YuenChief Financial OfficerPankaj TiwariChief Information Officer & Executive VPMichaella CorsoVice President-Clinical AffairsKey CompetitorsNovoCureNASDAQ:NVCRTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDInspire Medical SystemsNYSE:INSPShockWave MedicalNASDAQ:SWAVView All CompetitorsInsiders & InstitutionsCongress Wealth Management LLC DE Sold 1,955 shares on 2/2/2023Ownership: 0.021%ProShare Advisors LLCSold 572 shares on 2/2/2023Ownership: 0.008%Profund Advisors LLCBought 70 shares on 2/2/2023Ownership: 0.004%Concorde Asset Management LLCSold 372 shares on 2/2/2023Ownership: 0.003%Simplex Trading LLCBought 600 shares on 2/2/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PEN Stock - Frequently Asked Questions Should I buy or sell Penumbra stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares. View PEN analyst ratings or view top-rated stocks. What is Penumbra's stock price forecast for 2023? 13 Wall Street research analysts have issued 12-month target prices for Penumbra's stock. Their PEN share price forecasts range from $185.00 to $285.00. On average, they predict the company's stock price to reach $245.25 in the next year. This suggests that the stock has a possible downside of 7.5%. View analysts price targets for PEN or view top-rated stocks among Wall Street analysts. How have PEN shares performed in 2023? Penumbra's stock was trading at $222.46 at the beginning of the year. Since then, PEN stock has increased by 19.2% and is now trading at $265.19. View the best growth stocks for 2023 here. When is Penumbra's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our PEN earnings forecast. How can I listen to Penumbra's earnings call? Penumbra will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Penumbra's earnings last quarter? Penumbra, Inc. (NYSE:PEN) posted its quarterly earnings data on Monday, August, 9th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.19 by $0.02. The company earned $184.26 million during the quarter, compared to analysts' expectations of $170.77 million. Penumbra had a negative net margin of 3.68% and a positive trailing twelve-month return on equity of 0.45%. The firm's revenue for the quarter was up 75.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.30) EPS. What guidance has Penumbra issued on next quarter's earnings? Penumbra issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $840.00 million-$845.00 million, compared to the consensus revenue estimate of $860.97 million. What is Adam Elsesser's approval rating as Penumbra's CEO? 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees. What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM). What is Penumbra's stock symbol? Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN." Who are Penumbra's major shareholders? Penumbra's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.32%), Allspring Global Investments Holdings LLC (0.44%), New York State Common Retirement Fund (0.20%), AEGON ASSET MANAGEMENT UK Plc (0.18%), New York State Teachers Retirement System (0.09%) and Oak Harbor Wealth Partners LLC (0.09%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder. View institutional ownership trends. How do I buy shares of Penumbra? Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Penumbra's stock price today? One share of PEN stock can currently be purchased for approximately $265.19. How much money does Penumbra make? Penumbra (NYSE:PEN) has a market capitalization of $10.07 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.82) on an earnings per share basis. How many employees does Penumbra have? The company employs 3,800 workers across the globe. How can I contact Penumbra? Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232. This page (NYSE:PEN) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.